Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress.
Thrombolytic therapy is the most effective therapeutic strategy for the prevention of brain injury and reduction of mortality in patients with acute cerebral infarction. A combination of established thrombolytic therapy and effective neuronal protection therapy has more beneficial effects for patients with acute cerebral infarction. Edaravone (chemical name: 3-methyl-1-phenyl-2-pyrazolin-5-one) is a strong, novel scavenger of free radicals. Several lines of evidence have shown that edaravone has preventive effects on brain injury following ischaemia and reperfusion in patients with brain attack. This review focuses on putative mechanisms underlying the beneficial effects of edaravone on the atherosclerotic process in patients with stroke and on the possibility of edaravone-induced extension of the therapeutic time window in patients with acute cerebral infarction.
Higashi
Yukihito
Y
Hiroshima University, Graduate School of Biomedical Sciences, Department of Cardiovascular Physiology and Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. yhigashi@hiroshima-u.ac.jp
D000208:Acute Disease; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000378:metabolism; D000077553:Edaravone; D004730:Endothelium, Vascular / Q000378:metabolism*; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009569:Nitric Oxide / Q000502:physiology*; D018384:Oxidative Stress
D016166:Free Radical Scavengers; D009569:Nitric Oxide; D000077553:Edaravone; D000983:Antipyrine